Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

Francesco Bertolini1, Yuval Shaked, Patrizia Mancuso

  • 1Division of Hematology-Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy. francesco.bertolini@ieo.it

Nature Reviews. Cancer
|October 13, 2006

Related Experiment Videos

View abstract on PubMed

Summary
This summary is machine-generated.

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • The Multifaceted Circulating Endothelial Cell In Cancer: Towards Marker And Target Identification.

    • Circulating endothelial cells (CECs) and progenitors (CEPs) may serve as biomarkers in cancer. Measuring CEC and CEP levels could help monitor anti-angiogenic treatments and personalize drug dosing in oncology.

    Area of Science:

    • Oncology
    • Vascular Biology
    • Biomarker Discovery

    Background:

    • Elevated circulating endothelial cells (CECs) and progenitors (CEPs) are observed in various pathologies, notably cancer.
    • Preclinical data suggest CEC and CEP kinetics align with laboratory angiogenesis assays, which are not clinically applicable.
    • Emerging clinical evidence indicates CEC kinetics and viability may correlate with patient outcomes during anti-angiogenic therapy.

    Purpose of the Study:

    • To explore the potential of CEC and CEP measurements as surrogate markers.
    • To assess their utility in monitoring anti-angiogenic treatment efficacy.
    • To investigate their role in determining optimal biological doses for anti-angiogenic drugs.

    Main Methods:

    • Analysis of circulating endothelial cell (CEC) and progenitor (CEP) counts.
    • Correlation of CEC/CEP kinetics with angiogenesis assays (preclinical).
    • Clinical observation of CEC/CEP levels in cancer patients undergoing anti-angiogenic treatment.

    Main Results:

    • CEC and CEP kinetics show promise as indicators in preclinical models.
    • Clinical data suggest a correlation between CEC/CEP dynamics and treatment outcomes.
    • Potential for CEC/CEP measurement to reflect anti-angiogenic drug activity.

    Conclusions:

    • CEC and CEP measurements show potential as non-invasive biomarkers in oncology.
    • These markers could aid in monitoring patient response to anti-angiogenic therapies.
    • CEC/CEP analysis may facilitate personalized dosing of anti-angiogenic drugs, improving treatment strategies.

    Related Experiment Videos